Our pivotal strategy is identification of early market entry opportunities in immuno-oncotherapeutics and development of a product pipeline up to pre-clinical stage. Through collaborative early stage partnerships, Zumutor enables usage of our platforms to take a new mAb from sequence to scale.
Our biosimilar strategy involves out-licensing molecules to marketing partners for specific geographies. The model is turnkey partnership /solution/system beginning with early stage development, preclinical and clinical trials, and regulatory submissions enabling the partner to retain all newly generated IP.
OUR BUSINESS MODEL
Product and process development, licensee – manufacture along with market and outsourced animal toxicity studies and clinical trials serve partners in production of high-quality bio therapeutics.
In-house development of new biologics for ultimate enterprise value
PARTNERED INNOVATION ENGINE
Through early stage partnerships, Zumutor enables usage of protein display platforms. This involves a collaborative approach through development and potential market reach.
Licensing of biosimilars for time to market
Zumutor also collaborates closely with several key members of academia such as
Zumutor Biologics Inc. is a niche, innovation driven biologics company registered in the state of Delaware, with its office in Woburn, MA. Expertise and acumen of the Zumutor team is focused on development of new products through patent-pending technology platforms in our state of the art R&D facility in India
Zumutor also offers differentiated services ranging from co-development of monoclonal antibodies to recombinant technology based biosimilars